The Giants Shoulder #74 Psychedelics Expert: Who is Blocking Psychedelic Research? Cannabis Vs Alcohol, MDMA & Ayahuasca
Nov 13, 2025
Dr. Grace Blest-Hopley, a pioneering neuroscientist and psychedelics researcher focused on trauma and women's health, shares her groundbreaking insights. She discusses the contrasting risks of cannabis and alcohol, dispels myths about cannabis and psychosis, and highlights the therapeutic potential of MDMA for PTSD. Grace reveals why the FDA rejected MDMA trials and explores how psychedelics can treat addiction by rewiring the brain. She emphasizes the importance of cultural contexts and community in healing, and anticipates exciting future developments in psychedelic research.
AI Snips
Chapters
Transcript
Episode notes
Veterans’ Transformations In Amazon Retreats
- Dr. Grace Blest-Hopley watched veterans at Heroic Hearts transform after psychedelic retreats in the Amazon.
- She reports long-lasting improvements in depression and PTSD measures from those experiences.
Verify Science, Ignore Sensational Headlines
- Don't trust sensational headlines; read primary studies and question media summaries.
- Use available tools and AI to synthesize evidence and make informed personal choices.
Why MDMA Hit Regulatory Snags
- The FDA rejected MDMA for PTSD due to trial conduct, unblinding, and documentation concerns, not clear lack of efficacy.
- Rigorous regulatory standards force thorough trials even when real-world evidence looks strong.